Flecainide Shortage: What Providers and Prescribers Need to Know in 2026

Flecainide is not currently on the FDA's national drug shortage list, but many patients across the country are struggling to fill their prescriptions due to localized pharmacy stock gaps. For cardiologists, electrophysiologists, and primary care providers managing antiarrhythmic therapy, understanding the current availability landscape and having contingency plans in place is essential to maintaining continuity of care.

Current Availability Status

As of 2026, flecainide acetate (brand: Tambocor) is not listed as an active FDA shortage. Generic flecainide has been commercially available since 2004, and multiple manufacturers currently produce the 50 mg, 100 mg, and 150 mg tablet strengths.

However, real-world pharmacy-level availability is inconsistent. The 50 mg strength appears to experience the most frequent regional stock gaps. Rural patients and those in areas with limited pharmacy density face disproportionate challenges. Providers should expect to receive calls from patients who cannot fill flecainide prescriptions, even without a formal shortage.

Why This Is a High-Stakes Availability Issue

Unlike antihypertensives or statins, where a brief interruption in therapy has a gradual physiological impact, antiarrhythmic discontinuation carries acute risks. Patients on flecainide for paroxysmal AFib, PSVT, or ventricular arrhythmias face a direct risk of arrhythmia recurrence if doses are missed.

The CAST trial established that flecainide's proarrhythmic risk is context-dependent — it is safe in structurally normal hearts but dangerous in post-MI and structural heart disease patients. Abrupt discontinuation does not carry the same rebound risk as beta-blockers, but the loss of rhythm control in patients with symptomatic or hemodynamically significant arrhythmias remains a serious clinical concern.

Clinical Management of Flecainide Supply Gaps

When a patient contacts your office about flecainide unavailability, consider the following structured approach:

1. Assess urgency based on indication. A patient on flecainide for symptomatic PSVT or paroxysmal AFib with rapid ventricular response is at higher immediate risk from supply interruption than one with well-controlled, intermittent arrhythmia. Triage accordingly.
2. Help locate stock before switching. Direct your staff or the patient to medfinder for Providers, which calls pharmacies in the patient's area to locate available stock. Switching antiarrhythmics carries its own risks and should not be the first response to a temporary stock gap.
3. Consider a strength substitution if clinically appropriate. If a patient cannot find their prescribed strength (e.g., 50 mg) but 100 mg is available, a dose equivalency discussion may be warranted. Document any dosing changes and schedule ECG follow-up within 5 steady-state doses.
4. Authorize a 90-day supply. If not already prescribed, consider authorizing a 90-day supply through a mail-order pharmacy. This reduces refill frequency and reduces exposure to short-term pharmacy-level stockouts.

When to Consider Switching: Clinical Criteria

Switching antiarrhythmics should not be done reactively to a short-term supply gap. However, if supply disruptions are persistent and the patient is at ongoing risk, consider these alternatives based on patient profile:

• Structurally normal heart (PAF/PSVT): Propafenone (Rythmol SR) is the closest Class IC alternative. Outpatient initiation is possible in many cases.
• Paroxysmal/persistent AF (no severe HF): Dronedarone (Multaq) can be initiated outpatient. Note the major interaction between flecainide and dronedarone — a washout period is required.
• Mild to moderate structural heart disease: Sotalol requires in-hospital initiation with minimum 3 days of QTc monitoring. Amiodarone is appropriate for complex structural disease but requires long-term toxicity surveillance.
• Sustained VT or refractory AFib with structural disease: Amiodarone or dofetilide (Tikosyn, via REMS program) may be appropriate. Consider electrophysiology referral if not already involved.

Proarrhythmic Risk Context: The CAST Trial and Its Implications

The Cardiac Arrhythmia Suppression Trial (CAST) demonstrated that flecainide increased mortality (5.1% vs. 2.3% for placebo) in patients with asymptomatic, non-life-threatening ventricular arrhythmias who had a myocardial infarction in the prior 6 days to 2 years. This resulted in the FDA Black Box Warning restricting flecainide to life-threatening VAs and away from post-MI patients with non-life-threatening VAs.

For your patients already appropriately selected for flecainide (structurally normal hearts with PAF or PSVT, or life-threatening VT), the risk-benefit profile remains favorable. The CAST data does not change the clinical picture for correctly indicated patients — but it remains critical to ensure any patient proposed for flecainide has been appropriately screened.

Counseling Patients on Flecainide Supply Management

Proactive patient counseling at the time of prescribing can prevent many of these calls. Recommend the following to all flecainide patients:

• Fill prescriptions at least 5–7 days before running out
• Consider a 90-day supply through mail-order to minimize refill frequency
• Identify a backup pharmacy before they need it urgently
• Know the signs of arrhythmia recurrence and when to call the office
• Never stop flecainide without provider guidance

How medfinder Supports Provider Workflows

medfinder for Providers helps your office locate in-stock flecainide for patients without burdening your staff with pharmacy phone calls. By directing patients to medfinder.com/providers, you can ensure they get targeted pharmacy availability information quickly, reducing the chance of a dangerous medication gap.